CAVE (Cetuximab-AVElumab) lung: A single arm phase II clinical study of the combination of avelumab plus cetuximab in the second line treatment of metastatic non small cell lung cancer (NSCLC) patients
Latest Information Update: 22 Jun 2022
At a glance
Most Recent Events
- 01 Aug 2022 Results published in the International Journal of Cancer
- 07 Aug 2021 Status changed to recruiting.
- 15 Oct 2020 New trial record